New Buy Calls on PALI, LBRX, CCCC and DFTX: Targets, Cash and What the Analysts Are Betting On
Targets imply 88% to 314% upside, with cash into 2027-2030.
Targets imply 88% to 314% upside, with cash into 2027-2030.
Strong bullish case for its oral IBD therapy ahead of Phase 2 data.
The FDA has cleared Palisade Bio’s investigational new drug application for PALI-2108. The company will now start its Phase 2 ASCENTRA-UC trial in H2 2026.
Wolfe Research: PALI “Outperform” ($7) eyes 2027 ulcerative colitis trial; AVTX “Outperform” ($48) waits May LOTUS Phase 2 readout.
Analysts say PALI-2108 offers better safety and efficacy for ulcerative colitis compared to older PDE4 inhibitors.
Palisade Bio (PALI) receives Japan patent for PALI-2108, a targeted PDE4 inhibitor for ulcerative colitis and Crohn's disease, with Phase 2 trials planned for 2026.